Immunotherapy before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests pembrolizumab and an investigational drug (IO102-103) given before surgery for certain non-bulky head and neck squamous cell cancers. The goal is to shrink the cancer and improve chances of cure by treating it before the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing and able to sign informed consent (or assent if applicable).
- You are at least 18 years old when you sign consent.
- Your head and neck squamous cell cancer can be removed with surgery with curative intent, usually low-bulk/resectable stages.
- Your overall health is good enough (ECOG performance status 0 or 1).
- You can have tumor biopsies (a small tissue sample) before starting treatment and again during treatment.
- Your body can handle treatment based on lab/organ function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.